Quarterly ResultJun 9, 2026, 04:12 PM
BriaCell Q3 Net Loss $(7.24)M, 9-Month Loss $(22.8)M; Going Concern
AI Summary
BriaCell Therapeutics reported a net loss of $(7.24) million for the three months and $(22.81) million for the nine months ended April 30, 2026, with an accumulated deficit of $(134.34) million. The company issued a going concern warning due to sustained operating losses but successfully raised approximately $30.0 million in gross proceeds from a public offering in January 2026. BriaCell also increased its ownership in BC Therapeutics to 69.04% and in BriaPro to approximately 78% following a transaction.
Key Highlights
- Net loss for the three months ended April 30, 2026, was $(7,237,055).
- Net loss for the nine months ended April 30, 2026, was $(22,812,276).
- Accumulated deficit reached $(134,339,456) as of April 30, 2026.
- Net cash used in operating activities for the nine months was $(22,692,452).
- Raised approximately $30.0 million in gross proceeds from a public offering in January 2026.
- Total assets increased to $27,071,310 as of April 30, 2026, from $21,649,706.
- Research, development, and clinical trial expenses for nine months increased to $18,704,005.
- Increased ownership in BC Therapeutics to 69.04% and in BriaPro to approximately 78%.
Price Impact
More from BCTX